Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company headquartered in Pratteln, Switzerland, dedicated to the research, development, and commercialization of innovative medicines for patients with rare and debilitating diseases. The company primarily targets unmet medical needs in neuromuscular and mitochondrial disorders, including Duchenne muscular dystrophy (DMD), primary mitochondrial diseases, and neuro-ophthalmology conditions like LAMA2-deficient congenital muscular dystrophy. Notable products and efforts include treatments such as Agamree for DMD, distributed through strategic partnerships like the recent agreement with Ikris Pharma Network in India. Santhera Pharmaceuticals Holding AG operates subsidiaries across Europe, North America, and Asia to support its global pipeline advancement and market access. With expertise in mitochondrial health, it engages in collaborations to pioneer therapies in orphan disease segments often overlooked by larger firms. Employing around 44 to 79 staff, the company maintains a lean structure focused on high-impact biopharmaceutical innovation, contributing significantly to the biotechnology sector by enhancing quality of life for rare disease communities worldwide.